Dec. 7 (Bloomberg) -- Protalix BioTherapeutics Inc., a Carmiel-based biotechnology company, jumped the most in more than a week, narrowing the gap with its U.S.-traded shares.
The shares gained 6.5 percent, the most since Nov. 28, to 20.13 shekels, or the equivalent of $5.37, at 11:23 a.m. in Tel Aviv. Protalix closed at $5.39 yesterday in New York.
To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at email@example.com
To contact the editor responsible for this story: Claudia Maedler at firstname.lastname@example.org